Sponsor or institution

Clinical trials and research at argenx

• 21Clinical trials
• 41Countries

Newest trials

All recruiting trials (21)

• How ARGX-121 affects protein in IgA nephropathy

  This study tests whether ARGX-121 can change protein in urine and other kidney outcomes in adults with IgA nephropathy.

  Recruiting at 10 sites Phase 2 argenx · Valencia, California and 10 other locations · NCT07773727

• Empasiprubart IV in people with AChR-Ab positive generalized myasthenia gravis

  This study tests whether empasiprubart given by IV can help people with AChR-Ab positive generalized myasthenia gravis feel better and have fewer symptoms.

  Recruiting at 14 sites Phase 2 argenx · Carlsbad, California and 13 other locations · NCT07673627

• How Adimanebart Moves Through the Body in Healthy Adults

  This study tests how much adimanebart enters the blood and how it behaves in healthy adults after IV and SC dosing.

  Recruiting Phase 1 argenx · Montreal · NCT07673601

• Empasiprubart: how your body handles an autoinjector shot versus IV in healthy adults

  This study tests how empasiprubart behaves in the body when given as a subcutaneous autoinjector injections in the abdomen or thigh compared with IV, in healthy adults.

  Recruiting Phase 1 argenx · Mount Royal, Quebec · NCT07612020

• Empasiprubart by IV for adults with Multifocal Motor Neuropathy

  This study tests whether IV empasiprubart improves nerve thickness and hand function in adults with Multifocal Motor Neuropathy.

  Recruiting at 4 sites Phase 1 argenx · Tbilisi, K'alak'i T'bilisi and 3 other locations · NCT07610564

• Efgartigimod for Graves’ Disease in Adults

  This study tests whether giving efgartigimod under the skin helps thyroid function and is safe for adults with Graves’ disease.

  Recruiting at 51 sites Phase 3 argenx · Aalst, Oost-Vlass and 50 other locations · NCT07596849

• Impact of efgartigimod on overall disease experience in adults with generalized myasthenia gravis in Italy

  This study looks at real-world use of efgartigimod in adults with generalized myasthenia gravis to see how it affects their daily symptoms and experiences.

  Recruiting at 30 sites argenx · Acquaviva delle Fonti and 29 other locations · NCT07595653

• Efgartigimod for Graves' Disease in adults

  We are testing if efgartigimod given under the skin can help adults with Graves' disease by improving thyroid function and whether it is safe and tolerable.

  Recruiting at 35 sites Phase 3 argenx · Carlsbad, California and 34 other locations · NCT07570316

• ARGX-124 safety testing in healthy adults

  This study tests whether ARGX-124 is safe and measures its blood levels and immune response in healthy adults aged 18–65.

  Recruiting Phase 1 argenx · Montreal · NCT07377396

• ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis

  This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.

  Recruiting at 37 sites argenx · Carlsbad, California and 36 other locations · NCT07294170

• ARGX-119 IV for ambulant children aged 5 to under 18 with spinal muscular atrophy

  This trial will test whether IV ARGX-119, given with standard SMA therapies, is safe and can reduce muscle weakness and tiredness in children aged 5 to under 18.

  Recruiting at 18 sites Phase 2 argenx · Little Rock, Arkansas and 27 other locations · NCT07287982

• Adding empasiprubart to efgartigimod for AChR-antibody positive generalized myasthenia gravis

  This trial will test whether adding empasiprubart to efgartigimod infusions helps people with AChR-antibody positive generalized myasthenia gravis who have only had a partial response to efgartigimod.

  Recruiting at 33 sites Phase 2 argenx · Carlsbad, California and 32 other locations · NCT07284420

• Real-world efgartigimod use in adults with CIDP

  This study will see if efgartigimod helps adults with CIDP when given as part of routine clinical care.

  Recruiting at 22 sites argenx · Wilmington, North Carolina and 22 other locations · NCT07264426

• Efgartigimod IV for adolescents (12–17) with chronic immune thrombocytopenia

  This trial will try intravenous efgartigimod to see if it safely raises platelet counts in people aged 12 to 17 with chronic ITP.

  Recruiting at 26 sites Phase 2/3 argenx · Bordeaux and 25 other locations · NCT07194850

• Empasiprubart for adults with CIDP

  This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.

  Recruiting at 94 sites Phase 3 argenx · Birmingham, Alabama and 93 other locations · NCT07091630

• Empasiprubart versus IVIg for treating CIDP in adults

  This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.

  Recruiting at 107 sites Phase 3 argenx · Birmingham, Alabama and 106 other locations · NCT06920004

• Evaluating Efgartigimod PH20 SC in Adults with New-onset Generalized Myasthenia Gravis

  This study is testing a new treatment called efgartigimod PH20 SC to see if it helps adults who have recently been diagnosed with generalized myasthenia gravis feel better.

  Recruiting at 18 sites Phase 4 argenx · La Jolla, California and 17 other locations · NCT06909214

• Assessing the effects of efgartigimod IV in adults with primary immune thrombocytopenia

  This study is testing whether a new treatment called efgartigimod IV can help adults with primary immune thrombocytopenia feel better and improve their platelet counts.

  Recruiting at 93 sites Phase 3 argenx · Phoenix, Arizona and 93 other locations · NCT06544499

• Efgartigimod PH20 SC treatment for children with generalized Myasthenia Gravis

  This study is testing a new injection treatment for children with generalized Myasthenia Gravis to see how well it works and what the right dosage is.

  Recruiting at 19 sites Phase 2/3 argenx · Charlotte, North Carolina and 21 other locations · NCT06392386

• Safety assessment of efgartigimod exposure during pregnancy and breastfeeding

  This study is trying to see if efgartigimod is safe for pregnant women and breastfeeding mothers, and how it affects their babies.

  Recruiting at 4 sites argenx · Morgantown, West Virginia and 3 other locations · NCT06299748

• Safety study of patients treated with efgartigimod for Myasthenia Gravis

  This study is testing how safe the medication efgartigimod is for people with generalized Myasthenia Gravis who are just starting treatment or are in their first treatment cycle.

  Recruiting at 35 sites argenx · San Francisco, California and 34 other locations · NCT06298565

Quick answers

How many clinical trials run by argenx are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 41 countries. The most sites are in United States (14 trials), Italy (11 trials), Germany (10 trials), Spain (10 trials), Japan (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 2: 4, Phase 1: 4, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →